ERBB2 and breast cancer: In summary, the message conveyed by this study is that the TAZ score we developed appears extremely promising in predicting the individual likelihood to achieve a pCR to trastuzumab-based neoadjuvant therapy in Luminal B, HER2-positive BC patients.